Itamar Raz

Q: What Schools Are Affiliated With Itamar Raz

Itamar Raz is affiliated with the following schools: Hebrew University of Jerusalem, Tel Aviv University, Stanford University, University of Toronto, Kyoto University

Itamar Raz's AcademicInfluence.com Rankings

Itamar Raz

Biology

#8300

World Rank

#11353

Historical Rank

Genetics

#823

World Rank

#915

Historical Rank

Molecular Biology

#1041

World Rank

#1065

Historical Rank

Biochemistry

#1197

World Rank

#1316

Historical Rank

biology Degrees

Download Badge

Biology

Itamar Raz's Degrees

Bachelors Biology Tel Aviv University
Masters Biochemistry Tel Aviv University

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Itamar Raz Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Itamar Raz's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. (2001) (5564)
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. (2013) (3012)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes (2019) (2285)
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). (2006) (1767)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials (2019) (1687)
Type 2 diabetes mellitus (2015) (1613)
Low ratio of fat to carbohydrate oxidation as predictor of weight gain: study of 24-h RQ. (1990) (741)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus (2006) (628)
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial (2014) (564)
Oral Treatment With α-Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy (2006) (488)
β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial (2001) (485)
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. (2019) (424)
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials (2019) (415)
Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy (2003) (404)
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. (2019) (386)
Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial (2009) (343)
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. (2005) (332)
Insulin resistance associated with lower rates of weight gain in Pima Indians. (1991) (332)
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors’ Expert Forum (2017) (314)
Hyperglycemia and Cardiovascular Disease in Type 2 Diabetes Mellitus: Evidence-based Approach to Primary and Secondary Prevention (2003) (265)
Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus. (1990) (222)
Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. (2001) (217)
Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial (2016) (212)
Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. (2004) (211)
Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage (2005) (198)
Pre‐clinical Cushing's syndrome: an unexpected frequent cause of poor glycaemic control in obese diabetic patients (1996) (196)
Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. (2007) (192)
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. (2019) (192)
The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily (2013) (171)
Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors’ Expert Forum (2015) (167)
Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon (1999) (160)
Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial (2014) (146)
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. (2015) (145)
Pyridorin in type 2 diabetic nephropathy. (2012) (141)
T cell proliferative responses of type 1 diabetes patients and healthy individuals to human hsp60 and its peptides. (1999) (141)
Natural History of Cardiovascular Disease in Patients With Diabetes (2008) (140)
Personalized Management of Hyperglycemia in Type 2 Diabetes (2013) (139)
Glycemic Effects of Moderate Alcohol Intake Among Patients With Type 2 Diabetes (2007) (136)
Insulin pump therapy vs. multiple daily injections in obese Type 2 diabetic patients (2005) (136)
Reproducibility of glucose measurements using the glucose sensor. (2002) (132)
Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. (2012) (129)
Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus (2020) (127)
Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. (2004) (125)
Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? (2014) (125)
Basal-State Hyperinsulinemia in Healthy Normoglycemic Adults Is Predictive of Type 2 Diabetes Over a 24-Year Follow-Up (2009) (125)
Preclinical evaluation of pharmacokinetic-pharmacodynamic rationale for oral CR metformin formulation. (2001) (124)
Clinical, socioeconomic, and lifestyle parameters associated with erectile dysfunction among diabetic men. (2005) (121)
New and experimental approaches to treatment of diabetic foot ulcers: a comprehensive review of emerging treatment strategies (2004) (121)
Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. (2011) (117)
Cannabidiol arrests onset of autoimmune diabetes in NOD mice (2008) (117)
Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect. (2002) (116)
Treatment of new‐onset type 1 diabetes with peptide DiaPep277® is safe and associated with preserved beta‐cell function: extension of a randomized, double‐blind, phase II trial (2007) (115)
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial (2018) (112)
Abnormal Regulation of Protein Tyrosine Phosphatase Activities in Skeletal Muscle of Insulin-Resistant Humans (1991) (111)
The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach (2010) (110)
Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors’ Expert Forum (2016) (109)
Therapy in the Early Stage: Incretins (2011) (108)
Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. (2007) (106)
The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. (2011) (102)
Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients With Type 2 Diabetes (2019) (102)
DECLARE‐TIMI 58: Participants’ baseline characteristics (2018) (101)
Maggot therapy for the treatment of diabetic foot ulcers. (1998) (99)
Influences of Breakfast on Clock Gene Expression and Postprandial Glycemia in Healthy Individuals and Individuals With Diabetes: A Randomized Clinical Trial (2017) (95)
Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes (2008) (91)
Influence of Small-Group Education Sessions on Glucose Homeostasis in NIDDM (1988) (86)
Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes (2016) (85)
Noninvasive continuous glucose monitoring using photoacoustic technology-results from the first 62 subjects. (2007) (83)
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text (2007) (82)
Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. (2019) (80)
Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial (2017) (78)
Renal nitric oxide production during the early phase of experimental diabetes mellitus. (2000) (77)
Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk: A Secondary Analysis of a Randomized Clinical Trial. (2016) (76)
Impact of the U.S. Food and Drug Administration Cardiovascular Assessment Requirements on the Development of Novel Antidiabetes Drugs (2011) (74)
Post Hoc Subgroup Analysis of the HEART2D Trial Demonstrates Lower Cardiovascular Risk in Older Patients Targeting Postprandial Versus Fasting/Premeal Glycemia (2011) (74)
Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial (2015) (69)
Moderate exercise improves glucose metabolism in uncontrolled elderly patients with non-insulin-dependent diabetes mellitus. (1994) (69)
Diabetes: mellitus or lipidus? (2003) (68)
Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease (2018) (67)
Efficacy, dose–response relationship and safety of once‐daily extended‐release metformin (Glucophage® XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double‐blind, placebo‐controlled studies (2005) (67)
Epinephrine inhibits insulin-mediated glycogenesis but enhances glycolysis in human skeletal muscle. (1991) (66)
Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. (2008) (66)
Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. (2009) (65)
Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled Multicenter Trial (SAVOR-TIMI 53) of the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin (2014) (64)
Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management (2014) (63)
Beta-glycosphingolipids improve glucose intolerance and hepatic steatosis of the Cohen diabetic rat. (2009) (63)
Present and Future: Pharmacologic Treatment of Obesity (2011) (63)
Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study (2019) (62)
Guideline Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes (2013) (61)
Adolescent Obesity and Early-Onset Type 2 Diabetes (2020) (59)
Petition to replace current OGTT criteria for diagnosing prediabetes with the 1-hour post-load plasma glucose ≥ 155 mg/dl (8.6 mmol/L). (2018) (58)
Gender-specific care of diabetes mellitus: particular considerations in the management of diabetic women. (2008) (57)
Haemoglobin A1c is a predictor of COVID‐19 severity in patients with diabetes (2020) (55)
Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)‐TIMI 53 trial (2013) (54)
Antidiabetic effect of novel modulating peptides of G-protein-coupled kinase in experimental models of diabetes (2004) (54)
Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial (2015) (53)
The emerging role of VEGF in diabetic kidney disease. (2003) (52)
Impaired Glucose-Stimulated Insulin Secretion Is Coupled With Exocrine Pancreatic Lesions in the Cohen Diabetic Rat (2008) (51)
Lipotoxicity versus adipotoxicity—The deleterious effects of adipose tissue on beta cells in the pathogenesis of type 2 diabetes (2006) (51)
Effects of moderate intensity glycemic control after cardiac surgery. (2010) (51)
CD44 Involvement in Autoimmune Inflammations (2007) (51)
Immune modulation for prevention of type 1 diabetes mellitus. (2005) (50)
Treatment of Recent-Onset Type 1 Diabetic Patients With DiaPep277: Results of a Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial (2014) (50)
Increased Expression of Endothelin-Converting Enzyme-1c Isoform in Response to High Glucose Levels in Endothelial Cells (2004) (50)
Vitamins and trace metals status in non insulin dependent diabetes mellitus. (1991) (48)
Improvement in Glucose Control in Difficult-to-Control Patients With Diabetes Using a Novel Flash Glucose Monitoring Device (2016) (48)
The Role of Sulodexide in the Treatment of Diabetic Nephropathy (2012) (48)
Endocrinology: Insulin resistant and non-resistant polycystic ovary syndrome represent two clinical and endocrinological subgroups (1995) (48)
Clinical Assessment of Individualized Glycemic Goals in Patients With Type 2 Diabetes: Formulation of an Algorithm Based on a Survey Among Leading Worldwide Diabetologists (2015) (48)
Practical guidance on intensification of insulin therapy with BIAsp 30: a consensus statement (2009) (47)
Reduction in Glycated Hemoglobin and Daily Insulin Dose Alongside Circadian Clock Upregulation in Patients With Type 2 Diabetes Consuming a Three-Meal Diet: A Randomized Clinical Trial (2019) (46)
Insulin-like growth factor-1 (IGF-1) enhances recovery from HgCl2-induced acute renal failure: the effects on renal IGF-1, IGF-1 receptor, and IGF-binding protein-1 mRNA. (1995) (45)
LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial (2016) (45)
Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results (2009) (45)
An update on DPP-4 inhibitors in the management of type 2 diabetes (2016) (44)
Effect of Moderate Exercise on Serum Lipids in Young Men with Low High Density Lipoprotein Cholesterol (1988) (44)
The effect of a low carbohydrate energy-unrestricted diet on weight loss in obese type 2 diabetes patients – A randomized controlled trial (2011) (43)
Intensification of Insulin Therapy for Type 2 Diabetic Patients in Primary Care: Basal-Bolus Regimen Versus Premix Insulin Analogs (2013) (43)
Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes (2016) (42)
Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. (2008) (42)
Diabetes and radiocontrast media increase endothelin converting enzyme-1 in the kidney. (2008) (41)
Digital therapy in diabetes (2017) (41)
Response to Letter Regarding Article, "Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial". (2015) (41)
Dyslipidaemia in polycystic ovarian syndrome: different groups, different aetiologies? (1996) (40)
Predicting the 20‐year diabetes incidence rate (2007) (40)
Basal state hyperinsulinemia in healthy normoglycemic adults heralds dysglycemia after more than two decades of follow up (2012) (39)
Dose-response relationship of oral insulin spray in healthy subjects. (2005) (39)
Time course of lipopolysaccharide-induced nitric oxide synthase mRNA expression in rat glomeruli. (1999) (39)
Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk (2018) (39)
Oral administration of insulin in solid form to nondiabetic and diabetic dogs. (1994) (38)
Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. (2004) (38)
High frequency of pre-diabetes, undiagnosed diabetes and metabolic syndrome among overweight Arabs in Israel. (2005) (38)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Reply. (2019) (38)
Differences in mtDNA haplogroup distribution among 3 Jewish populations alter susceptibility to T2DM complications (2008) (38)
Insulin resistant and non-resistant polycystic ovary syndrome represent two clinical and endocrinological subgroups. (1996) (37)
Defective insulin response of phosphorylase phosphatase in insulin-resistant humans. (1992) (37)
The influence of zinc supplementation on glucose homeostasis in NIDDM. (1989) (36)
Impact of treatment with saxagliptin on glycaemic stability and β‐cell function in the SAVOR‐TIMI 53 study (2015) (36)
Diffuse Narrowing of Coronary Arteries in Diabetic Patients: The Earliest Phase of Coronary Artery Disease (1998) (36)
American Diabetes Association Indications for Statins in Diabetes (2009) (36)
Nonproteinuric diabetes-associated nephropathy in the Cohen rat model of type 2 diabetes. (2005) (36)
Different effects of bariatric surgical procedures on dyslipidemia: a registry-based analysis. (2017) (35)
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials (2022) (35)
Gene expression of insulin-like growth factor-I, its receptor and binding proteins in retina under hypoxic conditions. (1998) (35)
Different contributions of insulin resistance and beta‐cell dysfunction in overweight Israeli Arabs with IFG and IGT (2006) (34)
Prediction of progression from pre‐diabetes to diabetes: Development and validation of a machine learning model (2020) (34)
Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study. (2005) (33)
DAPAGLIFLOZIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND PRIOR MYOCARDIAL INFARCTION: A SUB-ANALYSIS FROM DECLARE TIMI-58 TRIAL (2019) (31)
Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58 (2020) (31)
Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58 (2020) (30)
Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c. (2016) (30)
Assessment of insulin resistance by a 13C glucose breath test: a new tool for early diagnosis and follow-up of high-risk patients (2010) (30)
Role of protein kinase C in the expression of endothelin converting enzyme-1. (2009) (30)
Role of Renal Nitric Oxide Synthase in Diabetic Kidney Disease during the Chronic Phase of Diabetes (2006) (30)
Metformin Use and Clinical Outcomes among Patients with Diabetes with or without Heart Failure or Kidney Dysfunction: Observations from the SAVOR-TIMI 53 Trial. (2019) (29)
The Importance of Short‐Term Off‐Target Effects in Estimating the Long‐Term Renal and Cardiovascular Protection of Angiotensin Receptor Blockers (2014) (29)
Efficacy and Safety of Taspoglutide Monotherapy in Drug-Naive Type 2 Diabetic Patients After 24 Weeks of Treatment (2012) (29)
The Individualized Target HbA1c: A New Method for Improving Macrovascular Risk and Glycemia Without Hypoglycemia and Weight Gain. (2009) (29)
Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin (2010) (28)
Hyperglycemia and its effect after acute myocardial infarction on cardiovascular outcomes in patients with Type 2 diabetes mellitus (HEART2D) Study design. (2005) (28)
Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. (2005) (28)
Early Insulinization to Prevent Diabetes Progression (2013) (27)
Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes (2017) (27)
Benefits of a simple glycaemic protocol in an orthopaedic surgery ward: a randomized prospective study (2012) (27)
Glucose tolerance factor extracted from yeast: oral insulin-mimetic and insulin-potentiating agent: in vivo and in vitro studies (2011) (27)
Upregulation of Mitochondrial Content in Cytochrome c Oxidase Deficient Fibroblasts (2016) (27)
Emerging gliptins for type 2 diabetes (2013) (26)
Corrigendum to “Insulin detemir and insulin aspart: A promising basal-bolus regimen for type 2 diabetes” [Diabetes Research and Clinical Practice 66 (2004) 193–201] (2006) (26)
Adiponectin and the development of diabetes in patients with coronary artery disease and impaired fasting glucose. (2006) (26)
Management of patients with diabetes and obesity in the COVID-19 era: Experiences and learnings from South and East Europe, the Middle East, and Africa (2020) (26)
Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy. (2003) (26)
β-glycosphingolipids ameliorated non-alcoholic steatohepatitis in the Psammomys obesus model (2014) (25)
DiaPep277® Preserves Endogenous Insulin Production by Immunomodulation in Type 1 Diabetes (2006) (25)
Cardiorenal outcomes with dapagliflozin by baseline glucose‐lowering agents: Post hoc analyses from DECLARE‐TIMI 58 (2020) (25)
40th EASD Annual Meeting of the European Association for the Study of Diabetes (2004) (25)
Assessing the levels of immunoglobulins in the saliva of diabetic individuals with periodontitis using checkerboard immunodetection. (2007) (25)
Hyperglycemia induces accumulation of glucose in human skeletal muscle. (1991) (25)
Disparate effects of exercise training on glucose tolerance and insulin levels and on ambulatory blood pressure in hypertensive patients (1993) (24)
The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58 (2021) (24)
Trace elements in blood cells of diabetic subjects. (1989) (24)
Frequency of cancer events with saxagliptin in the SAVOR‐TIMI 53 trial (2016) (24)
Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction (2019) (24)
The emerging role of NO and IGF‐1 in early renal hypertrophy in STZ‐induced diabetic rats (2011) (23)
Reduced negative surface charge on arterial endothelium of diabetic rats (1988) (23)
Pharmacokinetic evaluation of novel sustained-release dosage forms of valproic acid in humans. (1985) (23)
Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease. (2020) (23)
The role of insulin pump therapy for type 2 diabetes mellitus (2017) (23)
Dietary copper supplementation restores β-cell function of Cohen diabetic rats: a link between mitochondrial function and glucose-stimulated insulin secretion. (2013) (22)
Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial). (2019) (22)
Statin and Aspirin Therapy for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus (2012) (22)
Octreotide prevents the early increase in renal insulin-like growth factor binding protein 1 in streptozotocin diabetic rats. (1998) (22)
Patient clusters based on HbA1c trajectories: A step toward individualized medicine in type 2 diabetes (2018) (21)
Prevention of type 1 diabetes: today and tomorrow (2010) (21)
Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin. (2021) (21)
The use of continuous insulin delivery systems in severely insulin-resistant patients. (2001) (21)
PRECLINICAL EVALUATION OF PHARMACOKINETIC PHARMACOKINETIC PHARMACODYNAMIC RATIONALE FOR ORAL CR METFORMIN FORMULATION (2001) (21)
Activation of skeletal muscle casein kinase II by insulin is not diminished in subjects with insulin resistance. (1991) (21)
Cardiovascular disease in type 2 diabetics: epidemiology, risk factors and therapeutic modalities. (2003) (21)
Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE‐TIMI 58 study (2020) (21)
Diet and coronary heart disease in diabetes (2003) (21)
Oral Administration of β-Glucosylceramide for the Treatment of Insulin Resistance and Nonalcoholic Steatohepatitis: Results of a Double-Blind, Placebo-Controlled Trial. (2017) (21)
Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial. (2017) (20)
Epinephrine increases tricarboxylic acid cycle intermediates in human skeletal muscle. (1991) (20)
Incidence and Risk Factors for Mortality Following Bariatric Surgery: a Nationwide Registry Study (2018) (20)
A comparative pharmacokinetic study of valpromide and valproic acid after intravenous administration in humans (1985) (20)
Noninjectable methods of insulin administration. (2006) (20)
From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes (2021) (20)
Blood glucose levels should be considered as a new vital sign indicative of prognosis during hospitalization (2021) (19)
Digital health technology and diabetes management (2018) (19)
Diabetic foot disease is associated with reduced erythrocyte deformability (2016) (19)
Influence of chronic diabetes on tissue and blood cells status of zinc, copper, and chromium in the rat. (1988) (19)
Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial (2021) (19)
Early use of insulin in type 2 diabetes. (2005) (18)
Effect of short-term hyperglycemia on protein kinase C alpha activation in human erythrocytes. (2012) (18)
Heart failure: SGLT2 inhibitors and heart failure — clinical implications (2016) (18)
Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity or Mortality? No (2009) (18)
The addition of E (Empowerment and Economics) to the ABCD algorithm in diabetes care. (2015) (18)
Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS (2016) (18)
Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once‐weekly dulaglutide AWARD programme (2015) (18)
Prevalence of symptoms suggestive of gastroparesis in a cohort of patients with diabetes mellitus. (2013) (18)
Insulin Therapy: Future Perspectives. (2019) (18)
Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58 (2021) (18)
Metabolic and genomic dissection of diabetes in the Cohen rat. (2007) (17)
Effects of tamoxifen on insulin-like growth factors, IGF binding proteins and IGFBP-3 proteolysis in breast cancer patients. (2003) (17)
Altered tissue content of trace metals in diabetic hyperinsulinaemic sand rats (psammomys obesus) (1988) (17)
Treatment of Type 2 Diabetes: From “Guidelines” to “Position Statements” and Back (2016) (17)
Pharmacokinetics of valproic acid in volunteers after a single dose study. (1985) (17)
Challenges in developing endpoints for type 1 diabetes intervention studies (2009) (17)
Blood pressure and insulin in Ethiopian immigrants: longitudinal study. (1995) (16)
Skeletal muscle glycogen synthase activity in subjects with non-insulin-dependent diabetes mellitus after glyburide therapy. (1990) (16)
Childhood Pancreatitis and Risk for Incident Diabetes in Adulthood (2019) (16)
Blood pressure, glucose, insulin and lipids of young Ethiopian recent immigrants to Israel and in those resident for 2 years (1993) (16)
Insulin-like growth factor-I (IGF-I) and IGF-I receptor gene expression in the kidney of the chronically hypoinsulinemic rat and hyperinsulinemic rat. (1995) (16)
Can CD44 Be a Mediator of Cell Destruction? The Challenge of Type 1 Diabetes (2015) (16)
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. (2021) (16)
Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel (2020) (16)
Focus on childhood fitness, not just fatness (2006) (15)
Pharmacokinetics: The Effect of the Mode of Administration on the Hypolipidaemic Activity of Niacin: Continuous Gastrointestinal Administration of Low‐dose Niacin Improves Lipid‐lowering Efficacy in Experimentally‐induced Hyperlipidaemic Rats (1998) (15)
Significance of Neutrophil to Lymphocyte Ratio (NLR) and Platelet Lymphocyte Ratio (PLR) in Diabetic Foot Ulcer and Potential New Therapeutic Targets (2021) (15)
Cardiovascular and renal benefits of dapagliflozin in patients with short and long‐standing type 2 diabetes: Analysis from the DECLARE‐TIMI 58 trial (2020) (15)
Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease (2017) (15)
Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients with Cardiometabolic Disease. (2020) (14)
Prediction of hypertension by the insulinogenic index in young Ethiopian immigrants (1995) (14)
Factors Associated With Cardiovascular Events in Patients With Type 2 Diabetes and Acute Myocardial Infarction. (2016) (14)
Role of insulin and the IGF system in renal hypertrophy in diabetic Psammomys obesus (sand rat). (2003) (14)
Octreotide, a Somatostatin Analogue, Fails to Inhibit Hypoxia-induced Retinal Neovascularization in the Neonatal Rat (2000) (14)
Omega-loop gastric bypass is more effective for weight loss but negatively impacts liver enzymes: a registry-based comprehensive first-year analysis. (2017) (14)
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. (2021) (14)
Causes and Risk Factors for Death in Diabetes: A Competing-Risk Analysis From the SAVOR-TIMI 53 Trial. (2021) (13)
In-hospital treatment of hyperglycemia: effects of intensified subcutaneous insulin treatment (2007) (13)
Effect of Mild Hypoinsulinemia on Renal Hypertrophy: Growth Hormone/Insulin-Like Growth Factor I System in Mild Streptozotocin Diabetes (2002) (13)
Effect of acute N-nitro-L-arginine methyl ester (L-NAME) hypertension on glucose tolerance, insulin levels, and [3H]-deoxyglucose muscle uptake. (1997) (13)
Quality of life and patient-perceived difficulties in the treatment of type 2 diabetes. (2012) (13)
Evaluation of Long-Term Treatment Effect in a Type 1 Diabetes Intervention Trial: Differences After Stimulation With Glucagon or a Mixed Meal (2014) (13)
Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms (2012) (13)
Comparative pharmacokinetic evaluation of sustained-release theophylline formulations in dogs and humans (1987) (13)
Obesity in late adolescence and incident type 1 diabetes in young adulthood (2022) (12)
NAFLD in type 2 diabetes mellitus: Still many challenging questions (2020) (12)
The Berlin Declaration: A call to action to improve early actions related to type 2 diabetes. How can specialist care help? (2018) (12)
Chronic exogenous hyperinsulinaemia without sugar supplementation: acute salt-sensitive hypertension without changes in resting blood pressure (1993) (12)
Rapid activation of glycogen synthase and protein phosphatase in human skeletal muscle after isometric contraction requires an intact circulation (1995) (12)
244-OR: Effects of Dapagliflozin on the Urinary Albumin-to-Creatinine Ratio in Patients with Type 2 Diabetes: A Predefined Analysis from the DECLARE-TIMI 58 Randomised, Placebo-Controlled Trial (2019) (12)
Immigration to Israel during childhood is associated with diabetes at adolescence: a study of 2.7 million adolescents (2017) (12)
Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53. (2019) (12)
Antidiabetic Effect of Interleukin-1β Antibody Therapy Through β-Cell Protection in the Cohen Diabetes-Sensitive Rat (2014) (12)
Rectal administration of insulin. (1984) (12)
Evidence for a major gene affecting the transition from normoglycaemia to hyperglycaemia in Psammomys obesus (2005) (11)
Innovative Immune-Based Therapeutic Approaches for the Treatment of Type 1 Diabetes Mellitus (2005) (11)
Prevalence of diabetes mellitus among workers in Israel:¶a nation-wide study (1999) (11)
Insulin‐Induced Hypertension, l‐Arginine, and Endothelial Nitric Oxide Synthase in Pregnant Rats (2003) (11)
Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial (2016) (11)
Influence of moderate exercise on glucose homeostasis and serum testosterone in young men with low HDL-cholesterol level. (1988) (11)
Differential effects on kidney and liver growth of a non-viral hGH-expression vector in hypophysectomized mice. (2007) (11)
Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers (2004) (11)
Metabolic syndrome and microangiopathy. (2006) (11)
Improved pharmacokinetic and pharmacodynamic profiles of insulin analogues using InsuPatch, a local heating device (2014) (11)
The Berlin Declaration: A call to improve early actions related to type 2 diabetes. Why is primary care important? (2018) (10)
Preinfection glycaemic control and disease severity among patients with type 2 diabetes and COVID‐19: A retrospective, cohort study (2021) (10)
Herbal flavonoids inhibit the development of autoimmune diabetes in NOD mice: proposed mechanisms of action in the example of PADMA 28 (2010) (10)
INSULIN‐INDUCED RENAL DYSFUNCTION IN REGULAR SABRA RATS (1995) (10)
IL-1β hampers glucose-stimulated insulin secretion in Cohen diabetic rat islets through mitochondrial cytochrome c oxidase inhibition by nitric oxide. (2014) (10)
Abnormal regulation of ribosomal protein S6 kinase by insulin in skeletal muscle of insulin-resistant humans. (1993) (10)
Nitrendipine improves glucose tolerance and deoxyglucose uptake in hypertensive rats. (1994) (9)
Insulin degludec does not compromise efficacy or safety when given in a flexible once-daily dosing regimen compared to insulin glargine once daily at the same time each day in type 2 diabetes (2011) (9)
Serum adiponectin is associated with homocysteine in elderly men and women, and with 5,10-methylenetetrahydrofolate reductase (MTHFR) in a sex-dependent manner. (2010) (9)
The Barmer study: impact of standardized warming of the injection site to enhance insulin absorption and reduce prandial insulin requirements and hypoglycemia in obese patients with diabetes mellitus (2014) (9)
Adolescent Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Young Adulthood. (2020) (9)
Intensifying existing premix therapy (BIAsp 30) with BIAsp 50 and BIAsp 70: A consensus statement (2011) (9)
Comparative pharmacokinetic analysis of a novel sustained-release dosage form of diclofenac sodium in healthy subjects. (1988) (9)
The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus (2021) (9)
Insulin degludec in a flexible daily dosing regimen provides similar glycaemic control without increasing rates of hypoglycaemia compared to dosing the same time daily in type 2 diabetes (2011) (8)
The absorption of insulin: the absorption of insulin from the intestine in dogs (1989) (8)
Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans. (1984) (8)
Saxagliptin for the treatment of diabetes - a focus on safety (2016) (7)
Prevalence of glucose intolerance in young male Ethiopian immigrants. (1993) (7)
Adolescent BMI and early-onset type 2 diabetes among Ethiopian immigrants and their descendants: a nationwide study (2020) (7)
Relationship between Blood Glucose Control and Improved Cardiovascular Outcome after Stent Implantation in Diabetic Patients (2010) (7)
Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease (2018) (7)
Comparative pharmacokinetic analysis of novel sustained-release dosage forms of pentoxifylline in healthy subjects. (1988) (7)
Machine learning based study of longitudinal HbA1c trends and their association with all‐cause mortality: Analyses from a National Diabetes Registry (2021) (7)
Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. (2022) (7)
A combined approach to control valproic acid release via novel delivery system of valpromide: A kinetic and pharmacokinetic study (1986) (7)
Hexokinase kinetics in human skeletal muscle after hyperinsulinaemia, hyperglycaemia and hyperepinephrinaemia. (1994) (7)
Management of diabetic neuropathy. (2021) (6)
Pharmacokinetic analysis of sustained-release dosage forms of theophylline in humans: comparison of single and multiple dose studies. (1987) (6)
Gender-Specific Care of Diabetes (2007) (6)
A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes (2021) (6)
Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial (2020) (6)
Validity of diagnostic codes and estimation of prevalence of diabetic foot ulcers using a large electronic medical record database (2018) (6)
Diabetes epidemic and the thrifty gene. (2002) (6)
Hypoglycaemia following pancreatic allograft transplantation. (1998) (6)
Funding for practice-oriented clinical research (2006) (6)
[The guidelines for the diagnosis prevention and treatment of type 2 diabetes mellitus--2005]. (2006) (6)
For Debate Diabetes: mellitus or lipidus? (2003) (6)
The endogenous insulin-like growth factor system in radiocontrast nephropathy. (1998) (6)
Insulin Pump Therapy Versus Multiple Daily Injections in Obese Type 2 Diabetic Patients (2002) (6)
Calculating individualized glycaemic targets using an algorithm based on expert worldwide diabetologists: Implications in real‐life clinical practice (2018) (6)
Abstract 17503: Outcomes of Patients With Type 2 Diabetes and Known Congestive Heart Failure Treated With Saxagliptin: Analyses of the SAVOR-TIMI 53 Study (2013) (6)
Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58. (2022) (5)
Improved Postprandial Glucose Control Using the InsuPad Device in Insulin-Treated Type 2 Diabetes (2015) (5)
Diabetes therapy‐focus on Asia: second‐line therapy debate: insulin/secretagogues (2012) (5)
Response to Comment on Home et al. Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? Diabetes Care 2014;37:1499–1508 (2014) (5)
Treatment of Recent-Onset Type 1 Diabetic Patients With DiaPep277: Results of a Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial. Diabetes Care 2014;37:1392–1400. DOI: 10.2337/dc13-1391 (2014) (5)
Potential cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: current evidence and ongoing trials (2012) (5)
192Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58 (2019) (5)
Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes (2016) (5)
Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial) (2021) (5)
Complex impact of obesity on type 2 diabetes. (2005) (5)
Adolescent Thyroid disorders and Risk for Type 2 Diabetes in Young Adulthood. (2021) (5)
Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial (2006) (5)
A polygenic risk score predicts atrial fibrillation in cardiovascular disease. (2022) (5)
The relationship between inpatient hyperglycaemia and mortality is modified by baseline glycaemic status (2020) (5)
Adolescent Hypertension and Risk for Early-Onset Type 2 Diabetes: A Nationwide Study of 1.9 Million Israeli Adolescents. (2020) (5)
Effect of saxagliptin on renal outcome (2014) (5)
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial (2022) (5)
Managing labor and delivery of the diabetic mother (2009) (4)
Glucose Management by Registered Nurses for Adult Patients Hospitalized in Medical Wards: Structured Guidelines (Protocol) and Working Process (2010) (4)
Improved Insulin Absorption by Means of Standardized Injection Site Modulation Results in a Safer and More Efficient Prandial Insulin TreatmentA Review of the Existing Clinical Data (2014) (4)
Use of a Machine Learning Algorithm Improves Prediction of Progression to Diabetes (2018) (4)
Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR‐TIMI 53 outcome study (2017) (4)
Introduction to the 4th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) (2013) (4)
The effect of low dose octreotide administration on renal function and on gene expression of IGF-I axis components in experimental diabetes mellitus. (1998) (4)
SGLT-2 inhibitors for people with type 2 diabetes – Authors' reply (2019) (4)
The effect of hyperglycaemia on the absorption of glibenclamide in patients with non-insulin-dependent diabetes mellitus (2004) (4)
An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes (2019) (4)
Noninjectable methods of insulin administration. (2006) (4)
SGLT2 inhibitors for primary prevention of cardiovascular events (2019) (4)
Response by Mann et al to Letter Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial". (2019) (4)
Safety and Efficacy of a Novel Extended Release Formulation of Metformin in Patients with Type 2 Diabetes (2000) (4)
The Individualized Target HbA 1 c : A New Method for Improving Macrovascular Risk and Glycemia Without Hypoglycemia and Weight Gain (2009) (4)
The SONAR study-is there a future for endothelin receptor antagonists in diabetic kidney disease? (2019) (4)
Insulin Therapy and Hypoglycemia - Present and Future (2011) (3)
Stuttering and incident type 2 diabetes: a population-based study of 2.2 million adolescents. (2021) (3)
Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors’ Expert Forum. Diabetes Care 2016;39:1186–1201 (2017) (3)
Lipids and glucose in type 2 diabetes: what about the beta-cell and the mitochondria?: response to Boden and Laakso. (2005) (3)
Intervention of the Flash Glucose Sensing Technology on Glycemic Control and Treatment Satisfaction in Patients with Type 2 Diabetes Treated Intensively by Insulin—A Randomized Controlled Trial (2018) (3)
PROGNOSTIC IMPLICATIONS OF SIMULTANEOUS BIOMARKER ASSESSMENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: OBSERVATIONS FROM THE SAVOR-TIMI 53 TRIAL (2014) (3)
Cytochrome c Oxidase Activity as a Metabolic Regulator in Pancreatic Beta-Cells (2022) (3)
Abstract 16764: Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus and Heart Failure or Kidney Dysfunction - Observations From the SAVOR-TIMI 53 Trial (2016) (3)
Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial (2022) (3)
CHRONIC EXOGENOUS HYPERINSULINAEMIA ACCELERATES THE DEVELOPMENT OF HYPERTENSION IN SPONTANEOUSLY HYPERTENSIVE RATS (1995) (3)
EFFECTS OF DAPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS BODY MASS INDEX CATEGORIES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN THE DECLARE TIMI 58 TRIAL (2020) (3)
Monday, 27 August 2012 (2012) (3)
Introduction to the 5th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) (2016) (3)
Comment on Oosterwijk et al. High-Normal Protein Intake Is Not Associated With Faster Renal Function Deterioration in Patients With Type 2 Diabetes: A Prospective Analysis in the DIALECT Cohort. Diabetes Care 2022;45:35–41 (2022) (3)
Digital Diabetes Care System Observations from a Pilot Evaluation Study in Vietnam (2020) (3)
Comment on Shahraz et al. Do Patient Characteristics Impact Decisions by Clinicians on Hemoglobin A1c Targets? Diabetes Care 2016;38:e145–e146 (2016) (2)
Tackling obesity during the COVID‐19 pandemic (2020) (2)
Association of hyperglycemia and insulin with diabetic cardiovascular complications. (2003) (2)
Establishing priorities for diabetes action goals according to key opinion leaders and health professionals (2022) (2)
Comparative pharmacokinetic analysis of a novel sustained-release dosage form of theophylline in humans (2004) (2)
Adolescent cognitive function and incident early-onset type 2 diabetes (2021) (2)
Insulin-like growth factors (IGFs) and IGF-binding proteins in diabetic kidney disease. (1995) (2)
Comparison of glucose tolerance, lipids and blood pressure in young male Ethiopians from two different immigrations, 1989 and 1991. (1993) (2)
Comparison of HBA1c Goals Proposed by an Algorithm To Those Set By Different Members of Healthcare Teams Within the Dartmouth Hitchcock Health System. (2018) (2)
Autotomy is prevented by hyperglycemia and reduced by consuming sweet solutions (1987) (2)
Abstract 15035: Liraglutide Reduces Major Cardiovascular Events in Patients With Chronic Kidney Disease: Results From the Leader Trial (2017) (2)
Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients with Cardiometabolic Disease. (2021) (2)
Myopia and Early Onset Type 2 Diabetes: A Nationwide Cohort Study. (2021) (2)
Exogenous hyperinsulinemia and atherosclerosis in type 1 diabetic patients. (2013) (2)
Analysis: Accuracy Performance of the Medtronic NexSensor for 6 Days in an Inpatient Setting Using Abdomen and Buttocks Insertion Sites (2011) (2)
Response by Zelniker et al to Letter Regarding Article, "Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial". (2020) (2)
Letter Regarding Normal Albuminuria in Patients With Autopsy-Proven Advanced Diabetic Nephropathy (2022) (2)
Atrophy or hypertrophy in chronic renal ischemia: role of the IGF-I system. (2001) (2)
Abstract 15670: Relationship Between Baseline Cardiac Biomarkers and Cardiovascular Death or Hospitalization for Heart Failure in DECLARE-TIMI 58 (2019) (2)
Blood pressure measurement method not responsible for results of Brands et al. (1994) (2)
RISK STRATIFICATION WITH THE TIMI RISK SCORE FOR SECONDARY PREVENTION AMONG PATIENTS WITH DIABETES AND ELEVATED CARDIOVASCULAR RISK (2017) (2)
Effect of a primary-care-team focused diabetes educational program project on diabetes care quality indicators in a large health maintenance organization. (2021) (2)
Asthma in Youth and Early-Onset Type 2 Diabetes: A Nationwide Study of 1.72 Million Israeli Adolescents. (2021) (2)
Diabetic Proteinuria Revisited: Updated Physiologic Perspectives (2022) (2)
[Sodium glucose co-transporter 2 inhibitors in heart failure therapy]. (2020) (2)
Global Call for Free Academic Movement for International Dialogue (2012) (2)
Introduction to the Third World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) (2011) (1)
Interventions in diabetic patients after myocardial infarction (2003) (1)
Insulin degludec given in a flexible once-daily dosing regimen does not compromise efficacy or safety in type 2 diabetes (2013) (1)
NATRIURETIC PEPTIDES VERSUS A CLINICAL HISTORY OF HEART FAILURE FOR RISK PREDICTION IN PATIENTS WITH DIABETES (2019) (1)
Bilirubin levels and kidney function decline: An analysis of clinical trial and real world data (2022) (1)
Five years into the Israeli National Diabetes Program – are we on the right track? (2020) (1)
Effect of Injection Site Cooling and Warming on Insulin Glargine Pharmacokinetics and Pharmacodynamics (2019) (1)
Evaluation of Long-Term Treatment Effect in a Type 1 Diabetes Intervention Trial: Differences After Stimulation With Glucagon or a Mixed Meal. Diabetes Care 2014;37:1384–1391. DOI: 10.2337/dc13-1392 (2014) (1)
Thiazolidinediones in Cardiovascular Risk in Type 2 Diabetes Mellitus (2003) (1)
The Controversies in Obesity, Diabetes and Hypertension (CODHy) Meeting (2008) (1)
Bethanechol-Induced Cholinergic Toxicity in Diabetic Neuropathy (1990) (1)
Glucose intolerance in pregnancy and risk of early-onset type 2 diabetes: a population-based cohort study. (2023) (1)
Correction to: Incidence and Risk Factors for Mortality Following Bariatric Surgery: a Nationwide Registry Study (2018) (1)
Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes (2013) (1)
Abstract 15581: Effect of Dapagliflozin on Atrial Fibrillation/Flutter in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial (2019) (1)
1263-P: Adolescent Obesity and Incident Type 1 Diabetes in Young Adulthood (2022) (1)
Continuous subcutaneous insulin infusion—an opportunity for better care but not a “magic pill” (2017) (1)
Abstract 16139: A Targeted Proteomic Approach to Identify Circulating Biomarkers of Heart Failure Risk in Patients With Type 2 Diabetes Mellitus in DECLARE-TIMI 58 (2020) (1)
Abstract 15701: Relationship Between Cardiac Biomarkers and Major Adverse Cardiovascular Events in DECLARE-TIMI 58 (2020) (1)
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. (2023) (1)
MEDIATION ANALYSIS FOR DAPAGLIFLOZIN AND THE REDUCTION IN HOSPITALIZATION FOR HEART FAILURE IN DECLARE-TIMI 58 (2021) (1)
In anticipation of patient participation. (2009) (1)
Pharmacotherapy: ACCORD Blood Pressure and ACCORD Lipid: how low can we go? (2010) (1)
Introduction to the Second World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) (2009) (1)
Abstract 13702: A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients With Cardiometabolic Disease (2020) (1)
The continuing need for drug development and clinical trials in type 2 diabetes and its complications: introduction to the RDS special issue. (2011) (1)
Glycemic Targets and Prevention of Chronic Complications (2018) (1)
Pharmacokinetic analysis of valdice — a diethylcarbonate prodrug of valproic acid (1994) (1)
Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. (2022) (1)
Acute dysphasia associated with hypoglycemia. (1984) (1)
CLINICAL FACTORS ASSOCIATED WITH SUDDEN CARDIAC DEATH IN TYPE 2 DIABETES: INSIGHTS FROM THE SAVOR-TIMI 53 TRIAL (2016) (1)
1101-P: Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents: Analyses from DECLARE-TIMI 58 (2020) (1)
Author’s reply (2003) (0)
New treatments for diabetes. (2007) (0)
Acarbose in the Treatment of NIDDM Patients with Hyperlipidemia (1988) (0)
Insulin resistance associated with lower rates of weight gain in Pima (2017) (0)
303-OR: Effect of Dapagliflozin on Risk for Fast Decline in EGFR: Analyses from the DECLARE-TIMI 58 Trial (2020) (0)
Serum from type 2 diabetes patients consuming a three-meal diet resets circadian rhythms in cultured hepatocytes. (2021) (0)
Practical Approach to the Implementation of Diabetes Prevention (2013) (0)
Improved pharmacokinetic and pharmacodynamic profile of insulin analogs using InsuPatch , a local heating device Running Title : Local heating device and insulin action (2014) (0)
Sitagliptin Review of its Use in the Management of Type 2 (2010) (0)
GENETIC PREDISPOSITION TO ADIPOSITY IS ASSOCIATED WITH GREATER RISK OF SUBSEQUENT HEART FAILURE EVENTS IN INDIVIDUALS WITH TYPE 2 DIABETES MELLITUS (2023) (0)
410Heart failure risk stratification and efficacy of dapagliflozin in patients with type 2 diabetes mellitus (2019) (0)
788-P: The Cardiovascular and Renal Benefits of Dapagliflozin Are Independent of Baseline HbA1c: Analyses from DECLARE-TIMI 58 (2021) (0)
Feasibility of Creating a Diagnosis-Based Diabetic Foot Registry in a Large Health Care Provider (2018) (0)
PATTERNS OF ASPIRIN UTILIZATION AND OUTCOMES AMONG PATIENTS WITH DIABETES MELLITUS: A PROPENSITY SCORE MATCHED ANALYSIS FROM THE SAVOR-TIMI 53 TRIAL (2016) (0)
236-OR: Effects of Dapagliflozin on Progression of Diabetic Kidney Disease: Analysis from DECLARE-TIMI 58 Trial (2019) (0)
Subject Index Vol. 102, 2006 (2006) (0)
RELATIONSHIP BETWEEN CYSTATIN C, CREATININE-BASED EGFR, CARDIOVASCULAR EVENTS AND KIDNEY OUTCOMES IN DECLARETIMI 58 (2023) (0)
Biomedical research in Israel: does it have a future? (2000) (0)
Adolescent NAFLD & Type 2 Diabetes- Supplementary Material.docx (2020) (0)
PERFORMANCE OF A NOVEL GENETIC RISK SCORE TO IDENTIFY RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH CARDIOMETABOLIC DISEASE (2020) (0)
Contents, Vol. 71, 1984 (1984) (0)
Longitudinal observations on blood pressure, glucose, insulin and lipid levels in ethiopian immigrants (1995) (0)
BASELINE RENAL FUNCTION AND CARDIOVASCULAR RISK IN PATIENTS TREATED WITH SAXAGLIPTIN: OBSERVATIONS FROM THE SAVOR-TIMI 53 TRIAL (2014) (0)
A cc ep te d A rti cl e Digital therapy in diabetes Running title : Digital therapy in diabetes (2017) (0)
K009: Insulin-like growth factor-1 (IGF-1) levels determine atrophy or hypertrophy in chronic renal ischemia (2000) (0)
[THE CHALLENGE OF HEALTHY AGING WITH DIABETES: THE ISRAELI NATIONAL DIABETES COUNCIL GUIDELINES FOR TREATING OLDER PEOPLE]. (2021) (0)
Response to: ‘baseline differences in SAVOR trial’ – prespecified vs. post hoc analysis – a potential source of bias (2015) (0)
Characterizing Hypoglycemic Events during Saxagliptin Treatment in Type 2 Diabetes (2014) (0)
Editor's foreword (1988) (0)
Proposing a new design for self‐monitoring blood glucose logs (2016) (0)
Author response for "Pre‐infection glycaemic control and disease severity among patients with type 2 diabetes and COVID ‐19: A retrospective, cohort study" (2021) (0)
[Diabetic ketoacidosis--beware of cerebral edema!]. (2007) (0)
Short-term effectiveness of dapagliflozin versus DPP-4 inhibitors in elderly patients with type 2 diabetes: a multicentre retrospective study (2023) (0)
Editor's Foreword (2001) (0)
Maintenance of ambulatory diabetic patients on subcutaneous insulin pump. (1984) (0)
RF28 | PSUN302 Obesity at Late Adolescence and Incident Type 1 Diabetes in Young Adulthood (2022) (0)
blood flow during local heating Nitric oxide and neurally mediated regulation of skin (2015) (0)
The Association between Inpatient Hyperglycemia and Thirty-Day Mortality Is Modified by Type 2 Diabetes History (2018) (0)
Review for "Insulin Secretion is a Strong Predictor for Need of Insulin Therapy in Patients With New Onset Diabetes and HbA1c >10%, a post hoc analysis of EDICT study" (2021) (0)
Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58. (2022) (0)
[NATIONAL DIABETES PROGRAM IN ISRAEL AND IN SELECTED COUNTRIES - CURRENT STATE AND FUTURE TRENDS]. (2021) (0)
[778] AMELIORATION OF NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND THE METABOLIC SYNDROME IN DIABETIC COHEN RATS IS ASSOCIATED WITH REDUCED PANCREATIC INJURY (2007) (0)
DIAPEP277^ PRESERVES ENDOGENOUS INSULIN BY IMMUNOMODULATION IN TYPE 1 DIABETES (T1D) PATIENTS (2005) (0)
Abstract 10083: The Efficacy and Safety of Dapagliflozin in Women and Men With Type 2 Diabetes Mellitus: Insights From The DECLARE-TIMI 58 Trial (2019) (0)
Diabetic retinopathy screening in the emerging era of artificial intelligence Jakob Grauslund Using screening for the early detection of sight-threatening diabetic retinopathy is a pivotal step towards the reduction (2022) (0)
Subject Index, Vol. 71, 1984 (1984) (0)
BLOOD PRESSURE, SUBCLINICAL MYOCARDIAL INJURY AND CARDIOVASCULAR OUTCOMES AMONG PATIENTS WITH DIABETES AND HIGH CARDIOVASCULAR RISK: OBSERVATIONS FROM THE SAVOR-TIMI 53 TRIAL (2017) (0)
Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58 (2022) (0)
Prolonged response to glibenclamide in NIDDM patients in a normoglycemic state. (1994) (0)
GI262570, a non-thiazolidinedione, tyrosine-based PPARγ agonist improves overall metabolic control in combination with glibenclamide (2000) (0)
Components of the diets provided in the study ’ s metabolic component (2007) (0)
Cardiovascular complications in diabetic patients (2011) (0)
Response to Mastrototaro and Gross (2003) (0)
Efficacy and tolerance of insulin degludec administered once/day in a pattern unique flexible compared to insulin glargine once daily at a fixed time in patients with type 2 diabetes (T2D) (2012) (0)
Curalin supplement for patients with type 2 diabetes mellitus (2023) (0)
Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial. (2023) (0)
Human Antibodies & Hybridomas November (2013) (0)
[New insight into old disease: potential treatment of type 2 diabetes mellitus by bariatric surgery]. (2010) (0)
Creating Individualized HBA1C Targets Using Predictive Modeling (2017) (0)
Retraction Note: Abstracts of the 50th Annual Meeting of the EASD, Vienna 2014. ‘Evaluation of DiaPep277® treatment in type 1 diabetes by integrated analysis’ (2015) (0)
FIBROBLAST GROWTH FACTOR-23, CARDIORENAL OUTCOMES, AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM DECLARE-TIMI 58 (2022) (0)
Exocrine Insufficiency in Transplanted Pancreas Imitating Pancreatic Rejection (1994) (0)
PL-218: The weight loss or the procedure? Effect of different bariatric operations on hyperlipidemia (2009) (0)
Gender-specific treatment of the diabetic patient: Can we minimize risk factors in fetal programming? (2006) (0)
ASSESSMENT OF ATHEROTHROMBOTIC RISK IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (2022) (0)
Vaccination studies in type 1 diabetes. Authors' reply (2002) (0)
Endothelial Dysfunction in Diabetes: The Role of Protein Kinase C (2008) (0)
Primary prevention of type 2 diabetes: how do we do it? (2004) (0)
Reply to the letter of Draves et al. In response to the article: "Blood glucose levels should be considered as a new vital sign indicative of prognosis during hospitalization" (Kesavadev et al.)". (2021) (0)
MMC celebrating 6 years of experience and expansion (2022) (0)
ia ls Diabetes Epidemic and the Thrifty Gene (2002) (0)
[HEMOGLOBIN A1C AND MORTALITY FROM COVID-19]. (2021) (0)
Randomized Trial Heart Failure, Saxagliptin and Diabetes Mellitus: Observations from the SAVOR - TIMI 53 (2014) (0)
Type 2 Diabetics, insulin degludec administered once/daily according to a flexible schema assured glycemic control similar to a daily administration according to a fixed hour schema without augmenting hypoglycemic episods (2012) (0)
[Surgical treatment of morbid obesity]. (2008) (0)
ResearchAssessment of insulin resistance by a 13 C glucose breath test : a new tool for early diagnosis and follow-up of high-risk patients (2015) (0)
Abstract 14799: Cardiovascular Risk Stratification and Efficacy of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the DECLARE-TIMI 58 Trial (2020) (0)
Issue Information (2019) (0)
Abstract 17270: Outcomes of Patients With Type 2 Diabetes at High Risk of Cardiovascular Events Treated With Saxagliptin: Outcomes by Baseline HgbA1c (2013) (0)
Prevention of Diabetes in Israel (2014) (0)
Efficacy and safety of dapagliflozin according to baseline blood pressure – observations from DECLARE-TIMI 58 Trlial (2020) (0)
The endogenous insulin-like growth factor system in radiocontrast nephropathy. (1998) (0)
9 Insulin Therapy and Hypoglycemia-Present and Future (2017) (0)
[DIABETES - PRESENT AND FUTURE]. (2021) (0)
Are we overtreating cardiovascular disease in diabetic patients (2013) (0)
Sitagliptin: a viewpoint by Itamar Raz. (2007) (0)
RISK OF KIDNEY DISEASE PROGRESSION AND EFFICACY OF SGLT2 INHIBITION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (2023) (0)
Myocardial changes in streptozotocin induced diatetic rats: morphometry in isolated perfused hearts (1993) (0)
[COMPARISON OF A RECOMMENDATION FOR A DESIRABLE HBA1C VALUE BY INTERNAL WARD PHYSICIANS, DIABETES PHYSICIANS AND AN APPLICATION, FOR DIABETES PATIENTS DISCHARGED FROM HOSPITALIZATION IN AN INTERNAL WARD]. (2021) (0)
Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: a patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials (2022) (0)
Characterization of Differentially Expressed Protein Biomarkers in Pancreatic Tissues Derived from the Cohen Diabetic Rat Model of Type 2 Diabetes (2007) (0)
Effect of sustained-release on the pharmacokinetics of theophylline in healthy subjects. (1985) (0)
Vaccination studies in type 1 diabetes (2002) (0)
DiaPep277(R) Shows Promise as a Therapeutic Strategy for Type 1 Diabetes (2012) (0)
[Primary care for type 2 diabetes]. (2004) (0)
INFLAMMATORY AND CARDIAC BIOMARKERS ARE ASSOCIATED WITH RENAL OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: INSIGHTS FROM SAVOR-TIMI 53 (2018) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Itamar Raz?

Itamar Raz is affiliated with the following schools:

Itamar Raz's Academic­Influence.com Rankings

Itamar Raz's Degrees

Similar Degrees You Can Earn

Why Is Itamar Raz Influential?

Itamar Raz's Published Works

Published Works

What Schools Are Affiliated With Itamar Raz?

Itamar Raz's AcademicInfluence.com Rankings